Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Mato on Ibrutinib-Based Combinations in CLL

November 21st 2019

Anthony R. Mato, MD, MSCE, discusses ibrutinib-based combinations in chronic lymphocytic leukemia.

Dr. Cohen on Fixed-Duration Therapy in CLL

November 21st 2019

Jonathon B. Cohen, MD, MS, discusses fixed-duration therapy in chronic lymphocytic leukemia.

Dr. Cohen on the Use of Chemoimmunotherapy in CLL

November 16th 2019

Jonathon B. Cohen, MD, MS, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

FDA Approval Sought for Ibrutinib/Rituximab in Frontline CLL/SLL

November 8th 2019

A supplemental new drug application has been submitted to the FDA for ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) for the first-line treatment of patients ≤70 years old with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Al-Sawaf on Testing for CKT in CLL

November 8th 2019

Othman Al-Sawaf, MD, discusses checking complex karyotype in patients with chronic lymphocytic leukemia.

Dr. Furman on Prognostic Markers in High-Risk CLL

November 7th 2019

Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.

Taking CLL Therapies From Bedside to Community

November 3rd 2019

Michael J. Keating, MBBS, has devoted much of his career to finding means of controlling chronic lymphocytic leukemia.

Dr. Smith on PI3K Inhibitors in CLL

November 2nd 2019

Mitchell R. Smith, MD, PhD, division director, Cancer and Blood Disorders, and professor of medicine, GW Cancer Center, discusses the use of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Wierda on the ASCEND Trial and BTK Inhibitor-Based Therapies in CLL

October 25th 2019

William G. Wierda, MD, PhD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Ublituximab Plus Ibrutinib Improves PFS in Relapsed/Refractory High-Risk CLL

October 25th 2019

The combination of ublituximab and ibrutinib improved progression-free survival, as determined by an Independent Review Committee, compared with ibrutinib alone in patients with relapsed/refractory high-risk chronic lymphocytic leukemia.

CLL Treatment Moves Toward Combo Approaches and CAR T-Cell Therapy

October 24th 2019

William G. Wierda, MD, PhD, discusses the evolving treatment paradigm in chronic lymphocytic leukemia and ongoing trials looking at novel approaches.

Dr. Smith on Frontline Treatment Considerations in CLL

October 24th 2019

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

Dr. Siddiqi on Rationale for the TRANSCEND CLL 004 Trial in CLL/SLL

October 23rd 2019

Tanya Siddiqi, MD, discusses the rationale for the phase I/II TRANSCEND CLL 004 trial investigating the use of the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Mato on Immunotherapy Options in CLL

October 22nd 2019

Anthony R. Mato, MD, MSCE, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia.

Dr. Wierda on Using CD19-Targeted CAR T Cells in CLL

October 21st 2019

William G. Wierda, MD, PhD, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia.

Rituximab Sets the Pace in Changing Lymphoma Landscape

October 18th 2019

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

Dr. Smith on Using Venetoclax Versus Ibrutinib in CLL

October 17th 2019

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia.

Dr. Gerson on Targeted Therapy Versus Chemotherapy in CLL

October 16th 2019

James N. Gerson, MD, discusses the emergence of targeted therapy in chronic lymphocytic leukemia.

Dr. Mato on Utilizing CAR T Cells in CLL

October 15th 2019

Anthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.

Novel Agents, Combos Transforming Treatment in MCL and CLL

October 14th 2019

James N. Gerson, MD, discusses exciting updates in mantle cell lymphoma and chronic lymphocytic leukemia and other potentially practice-changing trials on the horizon.